Michelle M. Mielke

Jan 16, 2025 | nature.com | Farwa Ali |Michelle M. Mielke |Clifford R. Jack |David S. Knopman |Prashanthi Vemuri |Ronald Petersen | +1 more

AbstractDeclining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are associated with worse gait performance.

Jun 20, 2024 | alz-journals.onlinelibrary.wiley.com | Michelle M. Mielke |Ryan Frank |Luke R. Christenson |Robert Reid

1 BACKGROUND Premenopausal bilateral oophorectomy (PBO) causes abrupt endocrine dysfunction (e.g., loss of estrogen, progesterone, testosterone, and an increase in gonadotropins). Studies suggest that females with PBO are at an increased risk of cognitive impairment and dementia,1-9 but few neuroimaging studies have been conducted to clarify the underlying pathogenesis.

Jun 12, 2024 | nature.com | Suzanne Schindler |Marc Suárez-Calvet |Ara Khachaturian |Michelle M. Mielke |Yan Hu |Soeren Mattke

AbstractAnti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance.

Jun 11, 2024 | nature.com | Michelle M. Mielke

AbstractIn the past 5 years, we have witnessed the first approved Alzheimer disease (AD) disease-modifying therapy and the development of blood-based biomarkers (BBMs) to aid the diagnosis of AD. For many reasons, including accessibility, invasiveness and cost, BBMs are more acceptable and feasible for patients than a lumbar puncture (for cerebrospinal fluid collection) or neuroimaging. However, many questions remain regarding how best to utilize BBMs at the population level.

Mar 19, 2024 | mayoclinicproceedings.org | Brian D. Lahr |Michelle M. Mielke |Kent Bailey

AbstractTo examine differences in the incidence and prevalence of diagnosed diabetes by county rurality. This observational, cross-sectional study used US Centers for Disease Control and Prevention data from 2004 through 2019 for county estimates of incidence and prevalence of diagnosed diabetes. County rurality was based on 6 levels (large central metro counties [most urban] to noncore counties [most rural]).